A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this research study is to assess if daily valacyclovir therapy for
suppression of HSV-2 reactivation is associated with a decrease in mucosal HIV shedding in
individuals co-infected with both HSV-2 and HIV.
Phase:
Phase 4
Details
Lead Sponsor:
University of Washington
Collaborators:
GlaxoSmithKline National Institutes of Health (NIH)